MedTrace Logo

Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia

NCT02440828 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-08-18

No results posted yet for this study

Summary

This study evaluates the addition of tobramycin inhalation treatment to standard intravenous therapy in the treatment of ventilator associated pneumonia.

Conditions

  • Ventilator Associated Pneumonia (VAP)

Interventions

DRUG

tobramycin inhalation

tobramycin inhalation 300 mg twice daily

DRUG

placebo

NaCl 0.9% inhalation 4 ml twice daily

Sponsors & Collaborators

Principal Investigators

  • Menno Van der Eerden, MD, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-01
Completion
2020-07-01

Countries

  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02440828 on ClinicalTrials.gov